The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

The FDA declared the shortage of Novo Nordisk's weight-loss drugs over, giving compounders until May to stop making alternatives. An industry group representing compounders is suing. Dr. Angela Fitch ...

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...